Evidence map›Paper›PMID 41782638›Full record

ArticleInternational journal of translational medical research and public health2025

Building Real-World Evidence Infrastructure to Improve Health and Healthcare in the United States: Part III-Questions for Translational Science and Action Theory.

Osman Nuri Yogurtcu, Laura E Gressler, Jens Eldrup-Jorgensen, Kashif Haqqi, Colin Shepard, Orestis A Panagiotou, Santiago J Molina, Philip P Goodney, Ali B Abbasi, Brian S Anderson and 4 more

Abstract read
In one paragraph

Article in International journal of translational medical research and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Osman Nuri YogurtcuOffice of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0003-4987-3753
Laura E GresslerDepartment of Pharmacy Practice, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jens Eldrup-JorgensenDivision of Vascular Surgery at Tufts University School of Medicine and the Society for Vascular Surgery Patient Safety Organization, Boston, MA, USA.ORCID 0000-0002-5358-0577
Kashif HaqqiPragmedic Solutions, Washington DC, USA.
Colin ShepardChief Medical Officer, Schmidt Initiative for Long COVID, Palo Alto, CA, USA.
Orestis A PanagiotouOffice of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0001-9604-8380
Santiago J MolinaDepartment of Sociology, Northwestern University, Evanston, IL, USA.ORCID 0000-0001-9049-518X
Philip P GoodneySection of Vascular Surgery, Department of Surgery, Dartmouth-Hitchcock Medical Center, The Dartmouth Institute, Lebanon, ME, USA.
Ali B AbbasiDepartment of Surgery, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1039-2832
Brian S AndersonChief Executive Officer, Coalition for Health AI, Sudbury, MA, USA.ORCID 0009-0000-0310-6925
Wilbur C HaddenDepartment of Sociology, The Center for Innovation at University of Maryland, College Park, MD, USA.ORCID 0000-0001-8572-2990
James E TchengDivision of Cardiology, School of Medicine, Duke University, Durham, NC, USA.ORCID 0000-0001-6231-5567
Julia SkapikInformatics for Health, Washington DC.
Gregory PappasOffice of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration, Silver Spring, MD, USA.

Funding

FDA HHS U01 FD006936Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Background and Objective: Previous work in this series has introduced real-world evidence (RWE), coordinated registry networks (CRNs), and systemic, coordinated, inter-organizational networks (SCIONs) theory. The application of SCIONs theory to CRNs illuminates how their structure and function foster trust and cooperation in a network of organizations to successfully address complex problems in healthcare. This third part in the series asks questions about how SCIONs theory can benefit CRNs and how the experience of CRNs can further develop the SCIONs theory. Methods: This manuscript analyzes reciprocal relationships related to SCIONs theory and CRN practice, examining how each can be used to benefit the other. While SCIONs theory has not yet formally been used to direct the development of a CRN, future application is proposed. Conversely, we explored how the practical experiences of CRNs can inform and refine our understanding of SCIONs, including identifying areas for theoretical development and through an exploration of the current limitations of CRNs. Results: The SCIONs theory may usefully direct CRN development in key leadership areas, including increasing human capital, encouraging organizational adaptiveness, expanding institutional capacity, mobilizing political engagement, and generating cooperative behavior. CRNs, guided by SCIONs theory, can offer a pathway towards a more efficient, equitable, and learning-oriented healthcare system. A comprehensive approach proposed for CRNs may facilitate the expansion of the evaluation component in SCIONs theory. Conclusion and Implications for Translation: CRN program managers should prioritize strategic approaches that foster human capital, organizational adaptability, and institutional capacity. Government agencies may consider investments in CRN as a way to build RWE infrastructure that improves quality and efficiency of healthcare broadly. Public discourse may benefit from a clearer understanding of the role of cooperation in society to address issues that government and markets are not well suited to address. The literature on SCIONs can support the non-profit literature in the way the business literature supports the for-profit sector.

Indexed as

Evidence-Based MedicineLearning Health SystemPublic HealthRegistries

Identifiers

PMID41782638
PMCPMC12954874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.